The impact of etanercept on retinal microcirculation and vascular dysfunction in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

被引：0
|
作者：
Neumann, T. [1 ]
Knoll, K. [1 ]
Betge, S. [2 ]
Jung, C. [2 ]
Otto, G. [1 ]
Wolf, G. [1 ]
Saemann, A. [1 ]
机构：
[1] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[2] Univ Klinikum Jena, Klin Innere Med 1, Jena, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2014年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] ETANERCEPT RETENTION RATES IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS
    Dongen, C. V.
    Kneepkens, E.
    Vogelzang, E.
    l'Ami, M.
    Krieckaert, C.
    van der Horst, I.
    Voskuyl, A.
    Nurmohamed, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1145 - 1145
  • [2] Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis
    Roy Fleischmann
    Imran Iqbal
    [J]. Drugs & Aging, 2007, 24 : 239 - 254
  • [3] Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Fleischmann, Roy
    Iqbal, Imran
    [J]. DRUGS & AGING, 2007, 24 (03) : 239 - 254
  • [4] Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
    Ruwaard, J.
    Ami, M. J. L'
    Kneepkens, E. L.
    Krieckaert, C. L. M.
    Nurmohamed, M. T.
    Hooijberg, F.
    van Kuijk, A. W. R.
    van Denderen, J. C.
    Burgemeister, L.
    Rispens, T.
    Boers, M.
    Wolbink, G. J.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (02) : 129 - 136
  • [5] Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
    Moura, Cristiano S.
    Choquette, Denis
    Coupal, Louis
    Bessette, Louis
    Bernatsky, Sasha
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [6] BIOLOGIC USE IN NHS PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Queen, Anton B.
    Siebert, Stefan
    [J]. RHEUMATOLOGY, 2016, 55 : 124 - 124
  • [7] Golimumab In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Oldfield, Vicki
    Plosker, Greg L.
    [J]. BIODRUGS, 2009, 23 (02) : 125 - 135
  • [8] GolimumabIn the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Vicki Oldfield
    Greg L. Plosker
    [J]. BioDrugs, 2009, 23 : 125 - 135
  • [9] The Treatment of Ankylosing Spondylitis and Psoriatic Arthritis with Etanercept: A Comprehensive Review
    Collamer, Angelique N.
    Battafarano, Daniel F.
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 27 - 43
  • [10] Rates of cardiovascular events in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials.
    Bathon, J.
    Fleischmann, R.
    Peloso, P.
    Chon, Y.
    Hooper, M.
    Lin, S-L
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S188 - S188
12345